Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities

被引:87
|
作者
Shaker, Mina [1 ]
Tabbaa, Adam [1 ]
Albeldawi, Mazen [1 ]
Alkhouri, Naim [1 ]
机构
[1] Cleveland Clin, Inst Digest Dis, Dept Gastroenterol & Hepatol, Cleveland, OH 44195 USA
关键词
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Liver cirrhosis; Liver transplantation; Metabolic syndrome; CHRONIC HEPATITIS-C; INSULIN-SENSITIZING AGENTS; CRYPTOGENIC CIRRHOSIS; METABOLIC SYNDROME; DIABETES-MELLITUS; RISK-FACTORS; HISTOLOGICAL SEVERITY; NATURAL-HISTORY; UNITED-STATES; STEATOHEPATITIS;
D O I
10.3748/wjg.v20.i18.5320
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is becoming rapidly one of the most common indications for orthotopic liver transplantation in the world. Development of graft steatosis is a significant problem during the posttransplant course, which may happen as a recurrence of pre-existing disease or de novo NAFLD. There are different risk factors that might play a role in development of graft steatosis including post-transplant metabolic syndrome, immune-suppressive medications, genetics and others. There are few studies that assessed the effects of NAFLD on graft and patient survival; most of them were limited by the duration of follow up or by the number of patients. With this review article we will try to shed light on post-liver transplantation NAFLD, significance of the disease, how it develops, risk factors, clinical course and treatment options. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:5320 / 5330
页数:11
相关论文
共 50 条
  • [31] Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries
    Holmer, Magnus
    Melum, Espen
    Isoniemi, Helena
    Ericzon, Bo-Goran
    Castedal, Maria
    Nordin, Arno
    Schultz, Nicolai Aagaard
    Rasmussen, Allan
    Line, Pal-Dag
    Stal, Per
    Bennet, William
    Hagstrom, Hannes
    LIVER INTERNATIONAL, 2018, 38 (11) : 2082 - 2090
  • [32] Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation
    Yuval A. Patel
    Carl L. Berg
    Cynthia A. Moylan
    Digestive Diseases and Sciences, 2016, 61 : 1406 - 1416
  • [33] Impact of body mass index in liver transplantation for nonalcoholic fatty liver disease and alcoholic liver disease
    O'Neill, Stephen
    Napetti, Sara
    Cornateanu, Sorina
    Sutherland, Andrew I.
    Wigmore, Stephen
    Oniscu, Gabriel C.
    Adair, Anya
    HPB, 2017, 19 (12) : 1074 - 1081
  • [34] STEATOHEPATITIS RECURS FREQUENTLY AFTER LIVER TRANSPLANTATION FOR NONALCOHOLIC FATTY LIVER DISEASE
    Selzner, Nazia
    Adeyi, Oyedele
    Sandur, Verendra
    Gurram, Krishna
    Kashfi, Arash
    Therpondos, George
    Lilly, Leslie
    Levy, Gary
    Renner, Eberhard
    LIVER TRANSPLANTATION, 2009, 15 (07) : S108 - S108
  • [35] Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
    Mikolasevic, Ivana
    Filipec-Kanizaj, Tajana
    Mijic, Maja
    Jakopcic, Ivan
    Milic, Sandra
    Hrstic, Irena
    Sobocan, Nikola
    Stimac, Davor
    Burra, Patrizia
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (14) : 1491 - 1506
  • [36] Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
    Abenavoli, Ludovico
    Falalyeyeva, Tetyana
    Boccuto, Luigi
    Tsyryuk, Olena
    Kobyliak, Nazarii
    PHARMACEUTICALS, 2018, 11 (04)
  • [37] NEDDylation inhibition as a new potential therapy of nonalcoholic fatty liver disease
    Serrano-Macia, Marina
    Azkargorta, Mikel
    Simon, Jorge
    Lopitz Otsoa, Fernando
    Cardoso Delgado, Teresa
    Fernandez Ramos, David
    Gutierrez de Juan, Virginia
    Varela-Rey, Marta
    Goikoetxea, Naroa
    Fernandez Tussy, Pablo
    Apichueta, Patricia
    Saenz de Urturi, Diego
    Buque, Xabier
    Iruzubieta, Paula
    Crespo, Javier
    Lu, Shelly C.
    Mato, Jose M.
    Elortza, Felix
    Luz Martinez-Chantar, Maria
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E546 - E546
  • [38] Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease (NAFLD)
    Goland, S
    Shimoni, S
    Zhornitzcki, T
    Zhornitzcki, T
    Knobler, H
    Azulai, O
    Melzer, E
    Caspi, A
    Malnick, SD
    CIRCULATION, 2004, 110 (17) : 712 - 713
  • [39] Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease
    Lin C.-H.
    Kohli R.
    Current Gastroenterology Reports, 2020, 22 (10)
  • [40] Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease
    Zhou, Run
    Gu, Yunpeng
    Zhang, Binbin
    Kong, Tingting
    Zhang, Wei
    Li, Jie
    Shi, Junping
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2023, 14 (04)